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Background: Genomic complexity can predict the clinical course of patients affected by chronic lymphocytic leukemia
(CLL) with a normal FISH. However, large studies are still lacking. Here, we analyzed a large series of CLL patients and
also carried out the so far largest comparison of FISH versus single-nucleotide polymorphism (SNP) array in this
disease.
Patients and methods: SNP-array data were derived from a previously reported dataset.
Results: Seventy-seven of 329 CLL patients (23%) presented with a normal FISH. At least one large (>5 Mb) genomic
aberration was detected by SNP array in 17 of 77 patients (22%); this ﬁnding signiﬁcantly affected TTT. There was no
correlation with the presence of TP53 mutations. In multivariate analysis, including age, Binet stage, IGHV genes
mutational status and large genomic lesion, the latter three factors emerged as independent prognosticators. The
concordance between FISH and SNP array varied between 84 and 97%, depending on the speciﬁc genomic locus
investigated.
Conclusions: SNP array detected additional large genomic aberrations not covered by the standard FISH panel
predicting the outcome of CLL patients.
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introduction
The clinical course of patients affected by chronic lymphocytic
leukemia (CLL) is very heterogeneous and ranges from an
indolent and chronic disease to a rapidly progressing leukemia
or lymphoma necessitating aggressive treatment [1–3]. Several
parameters, such as staging, lymphocyte doubling time, CD38,
ZAP70, the mutational status of the variable region of the
immunoglobulin heavy chain (IGHV) and the presence of
speciﬁc genomic aberrations, are often used to stratify patients
based upon their expected clinical outcome [2–5]. A prognostic
model based on genomic aberrations (del 13q14.3, del 11q22.3,
del 17p13.1, trisomy 12) detected by ﬂuorescent in situ
hybridization (FISH) is also largely used [3, 6].
In the last few years, high density, single-nucleotide
polymorphism (SNP) genomic arrays (SNP arrays) proved to
be efﬁcient techniques to identify genetic aberrations in
malignant cells [7]. The major advantage of this approach in
comparison to FISH is that the whole genome can be scanned
for genomic aberrations at once and not only at a limited
number of regions. Moreover, recent data have shown that the
prediction of the outcome of CLL patients might be improved
by the use of SNP arrays. The detection of individual genetic
aberrations other than the ones detected by the standard FISH
panel [8], or of an overall increased genomic complexity [9, 10]
or of the capability to measure the size of the genomic
aberrations [11–13], all appear to have clinical implications,
better deﬁning the clinical outcome of CLL patients. Very
recently, by carrying out cytogenetic analysis with DSP30/IL2
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stimulation of CLL cells, Rigolin et al. [14] have shown that the
presence of an abnormal karyotype correlates with a shorter
time to ﬁrst treatment (TTT) and shorter overall survival (OS).
Although, in the last few years several investigators have
described the application of microarrays in CLL [8, 10, 15–22],
only a few of them have reported a detailed comparison with
FISH, including the clinical implication of using a SNP array
instead of the FISH panel to predict the outcome at diagnosis.
In order to evaluate whether SNP array can better deﬁne the
outcome of CLL patients with a normal FISH and can replace
FISH, we analyzed a large group of CLL patients, characterized
with both SNP array and the standard FISH panel.
materials and methods
tumor panel
CLL samples from a previously published series were investigated [8]. All
samples were collected at diagnosis and had an immunophenotypic score
of >3 according to Matutes et al. [23]. Patients provided informed consent
in accordance with local institutional review board requirements and the
Declaration of Helsinki. The study was approved by the Ethical Committee
of Bellinzona. CLL diagnosis and management were based on the National
Cancer Institute working group criteria [3]. Cases of monoclonal B-cell
lymphocytosis were discarded. Baseline clinical and molecular
characteristics have been collected as previously described [8]. The FISH
panel interrogated deletions at 13q14.3, 11q22, 17p13 and trisomy 12 [8].
SNP arrays
Copy-number data, obtained from high-molecular-weight genomic DNA
of CLL patients using the Genome-Wide Human SNP Array Version 6.0
(Affymetrix, Santa Clara, CA), were derived from a previously reported
dataset [8]. The bioinformatics pipeline used for the identiﬁcation of copy-
number alterations is described in detail by Rinaldi et al. [8]. In addition,
raw and smoothed copy-number values of each sample were plotted for
quality assessment. Copy-number aberrations >5 Mb were identiﬁed by
ﬁltering on segment size and conﬁrmed by visual inspection of the plotted
genomic proﬁles. The cut-off was stabilized according to a previously
published experience [24]. Validation of 13q14.3 losses was carried out
using real-time PCR, as previously described [25]. TP53 gene mutations
were evaluated as previously described [26].
statistical analysis
TTT was measured from the date of diagnosis until ﬁrst treatment or, for
untreated patients, to last follow-up. OS was measured from the date of
diagnosis to the last follow-up or death by any cause. The cumulative
probability of OS and TTT were plotted as curves according to the Kaplan–
Meier [27] method. A log-rank test was used to investigate the impact on
OS and TTT of categorical variables. Cox’s proportional hazard model [28]
was applied to evaluate the impact on OS and TTT of known clinical and
biological risk factors as well as the large genomic aberrations identiﬁed by
SNP array. A P-value of <0.05 was considered as statistically signiﬁcant.
Statistical analyses were carried out with the SPSS v.17.0.1 (SPSS, Chicago,
IL) and with Stata/SE v.12.1 (StataCorp, College Station, TX).
results
patient characteristics
The main patient characteristics are summarized in Table 1.
The median age at the time of diagnosis was 66 years (range
27–94). The majority of the patients (60%) were male and only
a few presented with advanced disease (28%). Unfavorable
prognostic factors, namely unmutated IGHV-genes, CD38
>30%, ZAP 70 >20%, beta2-microglobulin above the upper
normal value (UNV), lymphocyte doubling time <12 months
were registered in 39%, 36%, 39%, 61% and 18%, respectively.
genomic lesions affect the outcome of patients
with a ‘normal’ FISH
We investigated whether the presence of large genomic
aberrations (>5 megabases; Mb; Figure 1), not covered by the
probes used in the FISH panel, would affect the outcome in
patients with a ‘normal’ FISH, who are known to have an
intermediate outcome [6]. Seventy-seven of the 329 (23%) did
not present any lesion by FISH. Seventeen (21%) of these
patients with a normal FISH had additional DNA gains or
losses in the SNP array affecting different genomic regions
(Table 2). No TP53 mutations were detected in 13 of 17 cases
with genomic lesions that were analyzed for mutations. The
presence of at least one large genomic aberration determined a
signiﬁcantly shorter TTT [P = 0.0010; hazard ratio (HR) 2.8;
95% CI 1.5–5.5] (P = 0.001), but not OS (P = 0.098; HR 2.3;
95% CI 0.83–6.6) (Figure 2).
In multivariate analysis, including age >60 years, advanced
Binet stage disease, unmutated IGHV genes and the presence
of at least one large genomic lesion different from those
described by Döhner et al. [29], the latter three factors
emerged as independent prognosticators for TTT with a
signiﬁcance of P < 0.001, P < 0.001 and P = 0.036, respectively.
None of the examined variables maintained their signiﬁcance
in the same model according to OS (data not shown). In
particular, the presence of at least one large genomic aberration
identiﬁed patients with a shorter TTT among those with
mutated IGHV genes (P = 0.0002; HR 5.0; 95% CI 2.0–12.4)
(Figure 3, left panel) and with early stage disease (P = 0.005;
HR 3.22; 95% CI 1.36–7.62) (Figure 3, right panel).
SNP array and FISH give overall similar results
We compared the copy-number estimate obtained with
genome-wide DNA SNP array with the standard FISH, for the
Table 1. Clinical parameters assessed at the time of diagnosis
Parameter Number of patients Valid cases Percentage
Age >60 232 327 71
Gender (m:f) 196:133 329 60:40
Binet
Stage A 234 327 72
Stage B or C 93 28
IGHV mutational status
IGHV unmutated 127 326 39
IGHV mutated 199 61
CD38 >30% 117 321 36
Zap 70 >20% 112 284 39
Beta2-microglobulin >UNV 137 223 61
LDT <12 months 33 145 18
m, male; f, female; UNV, upper normal value; LDT, lymphocyte doubling
time.
Annals of Oncology original articles
Volume 24 | No. 5 | May 2013 doi:10.1093/annonc/mds646 | 
four loci investigated by the latter technique, in 329 CLL
patients. Since FISH is considered the gold standard for the
detection of prognostically relevant genomic aberrations in
CLL samples, cases with a negative SNP array and a positive
FISH were considered as false negative. As a whole, the
percentage of SNP array ‘false negative’ was relatively low,
affecting only between 2% and 8% of the whole CLL series
(Figure 3). The highest concordance between FISH and SNP-
array results was registered in samples with trisomy 12 (97%)
followed by del 11q (96%), del 17p (95%) and del 13q (84%)
(supplementary Figure S1A, available at Annals of Oncology
online).
Among the 18 cases with 17p loss by FISH, all the eight
samples with a loss detected by FISH in over 40% of the nuclei
were also detected up by SNP array while half of the 10 cases
with less than 40% of nuclei carrying the lesion were classiﬁed
as normal by genomic proﬁling (supplementary Figure S1B,
available at Annals of Oncology online).
Twenty-eight cases among those with del13q14.3, four
among those with trisomy 12, six among those with del
11q22.3 and two among those with del 17p13.1 were not
identiﬁed by FISH but by SNP array. Some of the observed
discordant results, especially those regarding del 13q14.3 and
trisomy 12, were likely due to different samples which might
Figure 1. Examples of three genomic proﬁles with genomic aberrations detected by SNP array in CLL patients with a normal FISH. Cases 08-515 presented
multiple lesions on chromosomes 4q, 6p, 6q, 8q, 9p, 12q, 13q, 14q, 17q, 22q. Case 09-414 presented a single gain at 3q. Cases 08-560 presented a single-
interstitial deletion at 4q. Black, raw copy-number values; red, smoothed copy-number values. X-axis, genomic mapping; Y-axis, log2 copy-number values.
Table 2. Large genomic aberrations spanning >5 Mb in patients with a normal FISH
Region Cytoband Type Candidate cancer genes Cases
chr1:225,493,922-235,530,710 1q42.12–q42.3 Loss – 2
chr3:145,475,764-176,735,018 3q24–q26.32 Gain – 2
chr6:30,403,481-39,295,352 6p21.33–p21.2 Gain TNF 2
chr6:87,049,197-125,406,247 6q14.3–q22.31 Loss PRDM1 1
chr6:136,647,604-142,392,181 6q23.3–q24.1 Loss TNFAIP3 1
chr7:125,307,489-141,917,586 7q31.33–q34 Loss – 2
chr8:106,322,626-146,131,926 8q23.1–qter Gain MYC 1
chr8:182,272-38,003,609 8p23.3–p11.23 Loss 1
chr9:21,302,665-32,558,663 9p21.3–p21.1 Loss CDKN2A 1
chr10:64,476,057-123,550,977 10q21.2–q26.13 Loss PTEN 1
chr14:70,726,012-79,783,628 14q24.2–q31.1 Loss – 2
chr18:51,454,691-77,917,301 18q21.2–q23 Gain BCL2, NFATC1 2
chr19:37,187,908-59,107,865 19q13.12–q13.43 Gain SPIB 1
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have been examined by SNP array and by FISH or even due to
false-positive FISH results. Real-time PCR carried out on a
series of samples discordant in terms of the 13q14.3 status
largely conﬁrmed the SNP-array results (supplementary
Figure S1C, available at Annals of Oncology online).
To ensure that the small discordances between the two
detection methods did not inﬂuence the prognostic value of
the assay, we applied the FISH-based prognostic model
developed by Döhner et al. [29] to our cohort according to
each method (Figure 4). The Kaplan–Meier curves were
comparable between FISH and SNP array, both for OS as for
TTT and the log-rank test was highly signiﬁcant. The results
were evaluated using a Cox multivariate regression model
adjusted for Binet stage, age at the time of diagnosis >60 years,
IGHV mutational status and the information regarding the
aberrations identiﬁed either by FISH or by SNP array. In both
the models and for both OS and TTT, the clinical
characteristics and del17p emerged as independent
prognosticators.
discussion
FISH is a powerful tool to predict the clinical course of
patients affected by CLL [2, 3, 6]. However, this technique
has some limitations and the SNP array provides additional
prognostic information [8–13] and could represent an
interesting comparison or, possibly, even an alternative
technique to be implemented in the initial workup of CLL
patients. In this article, in the so far largest comparison of
FISH versus SNP array in CLL, we showed that SNP array
was able to better deﬁne the prognosis of patients with a
‘normal’ FISH. Although SNP array provided results largely
overlapping with FISH, it had the drawback of a reduced
sensitivity in cases with aberrations present in only a low
percentage of neoplastic cells, which can be easily seen by
FISH.
An important beneﬁt of SNP array over FISH is the ability
to detect chromosomal aberrations not investigated by the
standard FISH panel or even not targeted by any commercially
available probes, but with a clinical relevance. In the present
Figure 3. TTT according to the presence of at least one genomic lesion detected by SNP array in CLL patients with a normal FISH, and with mutated
IGHV (left panel) or in Binet stage A (right panel).
Figure 2. TTT (left panel) and OS (right panel) according to the presence of at least one genomic lesion detected by SNP array in CLL patients with a
normal FISH.
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study, large genomic aberrations spanning >5 Mb were
detected by SNP array in 20% of the patients with a ‘normal’
FISH, which is in the absence of any of the four main genomic
aberrations targeted by the probes included in the standard
FISH panel (deletions at 13q14.3, 11q22, 17p13 and trisomy
12). Very importantly, the presence of at least one genomic
lesion exclusively detected by SNP array did not appear to be
associated with the presence of a mutated TP53 gene and
determined a signiﬁcantly shorter TTT, as also conﬁrmed by
multivariate analysis. Presumably due to the relatively indolent
disease course, no statistically signiﬁcant difference was noted
in OS. With this regard, some limitations of our study have to
be mentioned. Although based upon a very large series of
cases, the number of patients actually bearing a normal FISH
was relatively limited. Also, we have not validated the ﬁndings
in an independent series, which would be ideally represented
by a series of samples obtained from CLL patients enrolled in a
prospective clinical trial.
Of note, the presence of such large aberrations in patients
with a normal FISH was able to identify patients with a more
aggressive clinical course among those with mutated IGHV
genes. Interestingly, it has just been reported that also
conventional karyotyping, when carried out using DSP30/IL2
stimulation, is able to detect high-risk patients among this class
of individuals classiﬁed as intermediate risk by FISH [14].
These ﬁndings are in agreement with the prognostic role of
genomic complexity in CLL, in which additional genomic
aberrations would represent a clonal evolution possibly leading
to a shorter survival [9, 10, 14].
TP53 gene resulted unmutated in cases with a normal FISH
indicating that the phenotype we observed was unlikely due to
TP53 inactivation. Only integration with large-scale mutational
screening programs will reveal the relationship between these
lesions and the presence of the recently reported somatic
mutations targeting, among others, BIRC3, SF3B1, NOTCH1
and MYD88 [30–32].
The additional genomic lesions we detected did not occur at
speciﬁc sites but were found across the whole genome.
Nevertheless, some of the genes located in these regions,
namely TNF, PRDM1 and TNFAIP3, MYC, CDKN2A, PTEN,
BCL2 and NFATC1, are known or seem to play a role in
lymphoid neoplasms, including CLL. Other lesions did not
contain known candidate cancer genes (7q loss, 3q gain, 14q
loss), but were recurrent and already previously reported [20].
It is possible that some of these regions have a yet unknown
role in the pathogenesis of CLL, but their individually low
frequency makes it difﬁcult to identify a minimal common
region and deﬁne candidate genes (as well as choosing
appropriate FISH probes).
The comparison between SNP array and FISH revealed that
SNP array was able to detect the four prognostically relevant
FISH loci in nearly all cases with an overall concordance of
93%, in line with recent publications [10, 20, 21, 33]. In our
series, the rate of samples called as normal by SNP array in the
presence of a lesion detected by FISH (false negative) for
11q21 and 17p13 losses was nearly two-fold higher than for
trisomy 12 or del 13q14.3. This result was expected, since these
two lesions are known to be often subclonal, possibly present
even in a very low percentage of tumor cells [34, 35]. In this
study, the higher sensitivity of FISH was clearly evident, when
looking at the cases with 17p1.3 loss deﬁned by FISH: while all
cases with a percentage of >40% positive nuclei were detected
Figure 4. OS and TTT in 329 CLL patients according to the Döhner prognostic model by FISH (A and B; P < 0.001) or by SNP array (C and D; P < 0.001).
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by both FISH and SNP array, half of the cases with <40% of
nuclei carrying the loss in FISH were negative by genomic
proﬁling. In line with this, other authors have reported that
array based-karyotyping misclassiﬁed samples with a low
percentage of neoplastic cells carrying a genomic aberration
(up to 30%–40% of tumor cells in the sample) [15, 16, 20, 21].
This makes now impossible to fully replace the use of the
standard FISH panel with SNP array in all the patients. On the
other hand, it is of clinical importance that, although having a
high sensitivity, FISH cannot identify all the CLL patients with
a direct genetic inactivation of TP53: a percentage of patients
have somatic mutations inactivating TP53 in the absence of
17p loss, and these cases have an outcome overlapping the
ones with 17p deletion [26, 36]. Thus, the two techniques
could be complementary in identifying poor-risk patients
bearing a TP53 inactivation.
In line with previously published data [37], also false-
positive FISH positive results were observed, mainly for the
13q14 region and the lesions detected by SNP array only and
not by FISH were conﬁrmed by real-time PCR.
Over the past decade, there have been important advances in
the treatment of CLL [2], but the FISH-based prognostic
model developed >10 years ago [6] is still largely applied. In
order to validate the representativeness of our results in a
clinical setting, we applied this model to our cohort using data
generated by FISH or by SNP array. The Kaplan–Meier curves
were comparable between FISH and SNP array, both for OS
and for TTT, and the log-rank test was highly signiﬁcant, also
conﬁrmed in multivariate analysis.
As the time and effort needed for both FISH and SNP array,
as well their costs, are nowadays becoming less markedly
different, a workﬂow could be suggested in which CLL samples
would be ﬁrst analyzed with SNP array. Due to the lower
sensitivity of SNP array, in the absence of losses affecting the
TP53 gene locus, an interphase FISH test, investigating only
this speciﬁc locus, would be mandatory, since the inactivation
of TP53 can have important clinical consequences when
starting treatment [2, 3, 38]. Since DNA samples are routinely
obtained for the assessment of the IGHV mutational status [2,
3], but also, more and more, for the investigation of TP53 gene
somatic mutations [26, 36, 38], SNP array would not require
an additional blood sampling from the patients. As currently
done for FISH, genomic proﬁling could be repeated during the
follow-up, to identify the occurrence of new lesions, which
could change patients’ outcome. However, a prospective
evaluation of this approach and its possible integration with
the information derived from the mutational status of other
genes besides TP53 (for example, BIRC3, SF3B1, NOTCH1)
will be necessary. Moreover, it is important to stress that
the current guidelines indicate the evaluation of chromosomal
abnormalities at diagnosis or before treatment as
mandatory only in the context of clinical trials and as
‘advisable’ in the general practice [2, 3, 38]. The testing for
TP53 inactivation (by deletions or somatic mutations) can
now be seen as the only genetic diagnostic assay that might
affect the choice of the treatment, although there are still no
data derived from randomized trials, demonstrating the
superiority of a speciﬁc regimen for patients with inactivated
TP53 [4, 38].
In conclusion, here, the identiﬁcation of large genomic
lesions detected by SNP array represented an independent
prognostic factor in CLL patients with a normal FISH. SNP
array was also able to identify the most important known
prognostically relevant genomic aberrations of CLL. A
validation in prospective trials is needed.
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